While retrospective and single-arm studies have demonstrated the promising potential of VEN/AZA in various AML subgroups, this study will provide the first prospective head-to-head comparison of VEN/AZA versus SOC in patients with NPM1-mutated AML fit for intensive therapy. Here, NPM1 is linked to acute myeloid leukemia.